VERTIS-CV Results ' Disappoint, ' Raise More Questions VERTIS-CV Results ' Disappoint, ' Raise More Questions

The VERTIS-CV trial results presented at the ADA meeting raise more questions about the benefits of SGLT2 inhibitors than they answer, says Dr Harpreet Bajaj.Medscape Diabetes & Endocrinology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news